# BPC-157 Dosage in the Research Literature: Doses, Routes, Half-Life > How BPC-157 dosage is expressed in the research record: per-body-weight animal figures, the routes studied, the under-30-minute half-life, and why no validated human dosing exists. Per-body-weight animal-model figures, the routes studied, and the pharmacokinetics — reported as research data, never as human guidance. ## How BPC-157 doses are expressed in the research literature BPC-157 dosage in the published literature is expressed almost entirely per body weight, in animal models, and those figures are not human dosing guidance. Rodent studies commonly report doses around 10 micrograms per kilogram and 10 nanograms per kilogram, and some tendon work went as low as 10 picograms per rat [1]. The gastric-ulcer cytoprotection studies used 400 and 800 nanograms per kilogram in rats [4]. These numbers describe what was administered to a species in a controlled experiment — they do not translate into a human dose, and this page does not convert them. The human figures are minimal and come from pilot settings. A two-person intravenous safety pilot used 10 milligrams and then 20 milligrams by infusion; an interstitial-cystitis pilot used a single 10-milligram intravesical dose during cystoscopy [8][13]. These are the doses used in the only human studies that exist, reported as study facts. They are not a protocol, and the site provides no human dosing or administration instructions. ## BPC-157 half-life and pharmacokinetics The pharmacokinetics are among the best-defined parts of the record. In rats and dogs, BPC157 showed linear pharmacokinetics and an elimination half-life of under 30 minutes after intravenous and intramuscular dosing [2]. Intramuscular bioavailability was roughly 14 to 19 percent in rats and 45 to 51 percent in dogs, and the peptide broke down rapidly into small fragments that enter normal amino-acid metabolism, with excretion via urine and bile [2]. The short half-life is a consistent figure and shapes interpretation of every dosing schedule: the molecule clears quickly. ## Routes studied: injection and other administration in the literature BPC-157 injection is the dominant route in the animal record, but it is not the only one. Intraperitoneal injection is the most common route in rodent work; intramuscular and local or intra-lesional delivery are also frequent [1][4]. Intragastric and peroral routes were studied off the gastric-stability rationale [10]. The human pilots used parenteral and local routes specifically: intravenous in the safety pilot, intravesical in the interstitial-cystitis pilot, and intra-articular in the knee-pain case series [8][13]. Each route appears here as a research-administration fact, not a recommendation; the site gives no injection or administration instructions. ## Stability, reconstitution, and storage as research context BPC-157 is reported stable in human gastric juice, which underlies interest in oral and peroral administration; despite that, formal human oral pharmacokinetics are not established [10]. In research handling, lyophilized peptide is reconstituted in a diluent such as bacteriostatic water — a laboratory practice, not a validated clinical protocol. Storage and reconstitution figures in the literature are research-context details and should be read as such, not as preparation guidance. ## How long should I stay on BPC-157? No validated human dosing duration exists. Animal studies use fixed experimental schedules tied to each model's endpoint, and this site reports research figures only [1][9]. It does not provide human dosing or duration guidance, and no controlled human trial has established a duration. ## Why no human dosing appears here The reason is simply that the data does not exist. BPC-157 is not an FDA-approved drug, there is no labeled dose, and the human evidence is three small pilot studies [8][9][13]. Converting an animal per-kilogram figure into a human dose would be an invention, not a citation — so the site does not do it. The regulatory context for that absence, including the 2023 503A bulk-substance category, is on the [BPC-157 legal status and 503A category](/legal-status) page. --- An engraved register of the BPC-157 literature, read in gold on black — not a clinic, not a pharmacy, not a prescription, and nothing here is for sale.